Meryl Bartlett is an associate in the Washington, D.C. office of Latham & Watkins.
Ms. Bartlett represents pharmaceutical, biotechnology, medical device, digital health, food, dietary supplement, cosmetic, and consumer product companies on FDA regulatory compliance and enforcement matters. She counsels at all stages of the product life cycle, including, among others, pre-market regulatory communications and submissions, contract matters relating to clinical trials, non-patent exclusivity, post-market actions and recalls, and administrative interactions and appeals.
She also provides counsel on matters involving the Drug Enforcement Administration (DEA), US Department of Agriculture (USDA), and Federal Trade Commission (FTC). With the enactment of the Farm Bill in 2018, she also represents companies seeking to market CBD consumer products to navigate the evolving legal framework governing the industry.
In the transactional space, Ms. Bartlett advises investment banks, venture capital firms, private equity firms, and commercial lenders on regulatory diligence and disclosure matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.
A recognized thought leader, Ms. Bartlett frequently speaks and writes on healthcare and life sciences topics. She is a member of the review committee for the Food and Drug Law Journal’s H. Thomas Austern Writing Competition.
Ms. Bartlett was recently recognized for her professional excellence by Best Lawyers in their fourth edition of Best Lawyers: Ones to Watch in America for administrative/regulatory law.
She also maintains an active pro bono practice, currently serving as the firm’s liaison to the Legal Counsel for the Elderly and as a member of the Legal Counsel for the Elderly’s Young Lawyer’s Alliance.